We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Methylated DNA Blood Test Monitors Breast Cancer Progress and Treatment Response

By LabMedica International staff writers
Posted on 21 Apr 2014
Print article
Image: The Infinium HumanMethylation27 BeadChip Kit uses the Infinium Methylation Assay and is compatible with the iScan, HiScan, and Bead Array Reader systems (Photo courtesy of Illumina).
Image: The Infinium HumanMethylation27 BeadChip Kit uses the Infinium Methylation Assay and is compatible with the iScan, HiScan, and Bead Array Reader systems (Photo courtesy of Illumina).
An advanced assay that measures DNA hypermethylatation in blood samples can diagnose advanced breast cancer, as well as monitor tumor burden and treatment response in women with metastatic breast tumors.

The cMethDNA assay developed by investigators at John Hopkins University (Baltimore, MD, USA) is a quantitative multiplexed methylation-specific PCR assay for a panel of ten genes, consisting of novel and known breast cancer hypermethylated markers. These genes were selected by analyzing DNA methylation patterns in breast tissue (103 cancer, 21 normal) with the Illumina (San Diego, CA, USA) Infinium HumanMethylation27 Beadchip assay.

The 10-gene panel was validated using information from The Cancer Genome Atlas Project (Bethesda, MD, USA) breast cancer methylome database. The Cancer Genome Atlas Project is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.

The investigators evaluated the assay's ability to detect methylated tumor DNA in 52 blood samples—24 from patients with recurrent stage IV breast cancer and 28 from healthy women without breast cancer, and again in blood samples from 60 individuals—33 from women with all stages of breast cancer and 27 from healthy women. In both studies the blood test distinguished the patients with metastatic breast cancer from healthy women with accuracy up to 95%.

In a separate pilot study of 29 patients receiving drug treatment, the cMethDNA assay faithfully reflected patient response to chemotherapy.

"The goal is to develop a test that could be administered routinely to alert the physician and patient as soon as possible of a return of the original cancer in a distant spot. With the development of cMethDNA, we have taken a first big step toward achieving this goal," said senior author Dr. Saraswati Sukumar, professor of oncology at Johns Hopkins University. "Our assay shows great potential for development as a clinical laboratory test for monitoring therapy and disease progression and recurrence. If it is determined early that a treatment is not working, clinicians can save time and switch to a different therapy."

Results obtained with the cMethDNA assay were published in the April 15, 2014, issue of the journal Cancer Research.

Related Links:

John Hopkins University
Illumina
The Cancer Genome Atlas Project


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.